This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bio-Reference Laboratories' CEO Discusses Q3 Results - Earnings Call Transcript

The number of patients serviced during the current nine-month period was 5,762,000, which were 17% greater than the prior-year comparable quarter. Net revenue per patient for the nine-month period just ended was $83.57, which was 2% greater than the prior year comparable period. Earnings per share on net income were $1.05 per share for the nine-month period just ended, as compare to $0.92 per share in the prior year.

Thank you and I'll now turn the call over to Dr. Grodman.

Marc Grodman

Sam, thank you very much. I wouldn't care what word we use. Impressive, strong, Bio-Reference has demonstrated what we believe is a very impressive track record of growth and expansion for more than two decades and we are extremely pleased and proud to report another successful quarter of earnings, growth and innovation.

During the first half of this fiscal year, this current fiscal year, we introduced OnkoMatch, our tumor genotyping program. Inherigen, our pan-ethnic carrier screen, and GenCerv one of the groundbreaking new services in oncology and Women’s Health, and we spent years developing. We believe that these new offerings will pave the way for our continued growth and expansion in future years.

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs